{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:53:36Z","timestamp":1767833616438,"version":"3.49.0"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,5,30]],"date-time":"2007-05-30T00:00:00Z","timestamp":1180483200000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Desonide, a low potency corticosteroid, has been used widely as a topical treatment for inflammatory dermatoses for over 30\u2003years. A recent formulation advance has enabled the development of desonide 0.05% into a novel moisturizing aqueous gel (hydrogel) that is free of alcohol and surfactants. This multicenter, open\u2010label study evaluated the hypothalamic\u2010pituitary\u2010adrenal axis suppression potential, tolerability, and efficacy of this new Class VI topical steroid formulation in pediatric subjects with moderate\u2010to\u2010severe atopic dermatitis (mean body surface area\u2003=\u200351%). Forty children, aged 6\u2003months to 6\u2003years were enrolled and treated twice daily for 4\u2003weeks. Desonide hydrogel 0.05% was well tolerated and no treatment\u2010related adverse events were reported. No suppression of adrenal function was observed in subjects who completed the study without protocol violations related to cosyntropin administration or cortisol testing (<jats:italic>n<\/jats:italic>\u2003=\u200334). Of the subjects who completed the study with complications in cortisol testing (<jats:italic>n<\/jats:italic>\u2003=\u20033), there was one subject (1\/37\u2003=\u20033%) who had a low poststimulation cortisol level at week 4. Efficacy was demonstrated by marked improvement in overall disease state and in the signs and symptoms of atopic dermatitis. This study validates the systemic safety of a novel desonide hydrogel formulation in young pediatric patients and confirms the longstanding tolerability and efficacy profile of desonide.<\/jats:p>","DOI":"10.1111\/j.1525-1470.2007.00405.x","type":"journal-article","created":{"date-parts":[[2007,5,30]],"date-time":"2007-05-30T22:29:16Z","timestamp":1180564156000},"page":"289-295","source":"Crossref","is-referenced-by-count":29,"title":["Effect of Desonide Hydrogel 0.05% on the Hypothalamic\u2010Pituitary\u2010Adrenal Axis in Pediatric Subjects with Moderate to Severe Atopic Dermatitis"],"prefix":"10.1111","volume":"24","author":[{"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarmistha","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Calvarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Trancik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,5,30]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.033"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107773"},{"key":"e_1_2_7_4_2","unstructured":"IMS Health U.S.prescription data January 2004\u2013August 2006."},{"key":"e_1_2_7_5_2","volume-title":"Protopic\u00ae (tacrolimus ointment 0.03%, tacrolimus ointment 0.1% [for dermatologic use only])","year":"2006"},{"key":"e_1_2_7_6_2","volume-title":"Elidel\u00ae (pimecrolimus cream 1% for dermatologic use only)","year":"2006"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.118337"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(71)90256-0"},{"key":"e_1_2_7_9_2","first-page":"151","article-title":"Effect of desonide ointment, 0.05%, on the hypothalamic\u2010pituitary\u2010adrenal axis of children with atopic dermatitis","volume":"59","author":"Lucky AW","year":"1997","journal-title":"Cutis"},{"key":"e_1_2_7_10_2","first-page":"393","article-title":"Overview on desonide 0.05%: a clinical safety profile","volume":"3","author":"Wong VK","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90014-4"},{"key":"e_1_2_7_12_2","first-page":"44","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin JM","year":"1980","journal-title":"Acta Dermvenereol"},{"key":"e_1_2_7_13_2","first-page":"175","article-title":"Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis","volume":"6","author":"Hebert AA","year":"2007","journal-title":"J Drugs Dermatol"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-1470.2007.00405.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-1470.2007.00405.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T16:58:21Z","timestamp":1697129901000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-1470.2007.00405.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1525-1470.2007.00405.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-1470.2007.00405.x","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}